MA50080A - Méthodes d'utilisation du dantrolène pour traiter l'exposition à un agent neurotoxique - Google Patents

Méthodes d'utilisation du dantrolène pour traiter l'exposition à un agent neurotoxique

Info

Publication number
MA50080A
MA50080A MA050080A MA50080A MA50080A MA 50080 A MA50080 A MA 50080A MA 050080 A MA050080 A MA 050080A MA 50080 A MA50080 A MA 50080A MA 50080 A MA50080 A MA 50080A
Authority
MA
Morocco
Prior art keywords
dantrolene
methods
neurotoxic agent
treat exposure
treat
Prior art date
Application number
MA050080A
Other languages
English (en)
Inventor
Adrian Hepner
Original Assignee
Eagle Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eagle Pharmaceuticals Inc filed Critical Eagle Pharmaceuticals Inc
Publication of MA50080A publication Critical patent/MA50080A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MA050080A 2017-09-05 2018-09-05 Méthodes d'utilisation du dantrolène pour traiter l'exposition à un agent neurotoxique MA50080A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762554049P 2017-09-05 2017-09-05
US201862674406P 2018-05-21 2018-05-21

Publications (1)

Publication Number Publication Date
MA50080A true MA50080A (fr) 2020-07-15

Family

ID=63708449

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050080A MA50080A (fr) 2017-09-05 2018-09-05 Méthodes d'utilisation du dantrolène pour traiter l'exposition à un agent neurotoxique

Country Status (16)

Country Link
US (2) US20200383954A1 (fr)
EP (1) EP3678659B1 (fr)
JP (2) JP2020532555A (fr)
KR (1) KR20200047655A (fr)
CN (1) CN111093652A (fr)
AU (1) AU2018328131B2 (fr)
BR (1) BR112020004429A2 (fr)
CA (1) CA3074732A1 (fr)
IL (1) IL272847A (fr)
MA (1) MA50080A (fr)
MX (2) MX2020002485A (fr)
NZ (1) NZ762056A (fr)
SG (1) SG11202001749SA (fr)
UA (1) UA126688C2 (fr)
WO (1) WO2019050923A1 (fr)
ZA (1) ZA202001258B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020302992A1 (en) * 2019-06-28 2022-02-03 The Trustees Of The University Of Pennsylvania Intranasal dantrolene administration for treatment of Alzheimer's Disease
JP2024545570A (ja) * 2021-11-05 2024-12-10 クオラム イノベーションズ リミテッド ライアビリティ カンパニー 有機リン酸および他の有毒物質の毒性を防止または低減するための材料および方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7758890B2 (en) * 2001-06-23 2010-07-20 Lyotropic Therapeutics, Inc. Treatment using dantrolene
CA2516667C (fr) * 2003-03-04 2012-05-29 Lyotropic Therapeutics, Inc. Traitement au moyen de dantrolene
WO2013040501A1 (fr) * 2011-09-16 2013-03-21 Pharmathene, Inc. Compositions et combinaisons d'accepteurs biologiques organophosphorés et d'enzymes dégradant le hyaluronane, et leurs utilisations
EP4335505A3 (fr) * 2012-11-30 2024-06-05 The Regents of The University of California Activité anticonvulsivante de stéroïdes

Also Published As

Publication number Publication date
MX2020002485A (es) 2020-07-20
SG11202001749SA (en) 2020-03-30
EP3678659C0 (fr) 2025-12-17
UA126688C2 (uk) 2023-01-11
WO2019050923A1 (fr) 2019-03-14
KR20200047655A (ko) 2020-05-07
MX2023012415A (es) 2023-11-01
CA3074732A1 (fr) 2019-03-14
NZ762056A (en) 2025-10-31
EP3678659A1 (fr) 2020-07-15
JP2023055802A (ja) 2023-04-18
EP3678659B1 (fr) 2025-12-17
IL272847A (en) 2020-04-30
AU2018328131B2 (en) 2024-04-18
CN111093652A (zh) 2020-05-01
US20220087980A1 (en) 2022-03-24
AU2018328131A1 (en) 2020-03-12
ZA202001258B (en) 2023-10-25
RU2020112318A (ru) 2021-10-06
US20200383954A1 (en) 2020-12-10
BR112020004429A2 (pt) 2020-10-20
JP2020532555A (ja) 2020-11-12
RU2020112318A3 (fr) 2021-10-26

Similar Documents

Publication Publication Date Title
EP3496666A4 (fr) Dispositifs et procédés pour le traitement d'une insuffisance valvulaire
EP3452060A4 (fr) Polythérapie pour le traitement du cancer
EP3446194A4 (fr) Raccourcis d'application pour carplay
EP3526328A4 (fr) Polythérapie pour l'inhibition de c3
EP3504187A4 (fr) Utilisation de la pridopidine pour le traitement du déclin fonctionnel
EP3416638A4 (fr) Méthodes et composés pour la restauration de la fonction du p53 mutant
EP3383996A4 (fr) Dispositifs de simulation d'une fonction d'un tissu hépatique et leurs procédés d'utilisation et de fabrication
EP3474842A4 (fr) Compositions, dispositifs et méthodes pour le traitement d'un trouble lié à l'utilisation d'alcool
MA46791A (fr) Composés et procédés pour réduire l'expression d'atxn3
EP3411737A4 (fr) Croisement de guides d'ondes
FI4327866T3 (fi) Mirikitsumabi haavaisen paksusuolitulehduksen hoitoon
DK3891145T3 (da) Modulatorer af trex1
MA42999A (fr) Polythérapie pour le traitement de malignités
EP3678675A4 (fr) Nouvelle utilisation du sulfate de dextrane
MA45492A (fr) Vecteurs viraux pour le traitement de l'hyperactivité vésicale neurogène
EP3416645A4 (fr) Composés pour le traitement du paludisme
EP3360377A4 (fr) Établissement d'un appel vocal
EP3478284A4 (fr) Composés et compositions pour le traitement du cancer
MA45973A (fr) Combinaisons d'inhibiteurs de btk pour le traitement du myélome multiple
MA43051A (fr) Polythérapie pour le traitement d'une du vhc
MA50080A (fr) Méthodes d'utilisation du dantrolène pour traiter l'exposition à un agent neurotoxique
EP3568754C0 (fr) Suppression temporaire du traitement d'une demande d'opérande de stockage restreinte
MA54559A (fr) Polythérapie pour le traitement du cancer
MA50119A (fr) Découverte de règle de vecteur sémantique
EP2968598A4 (fr) Traitement après l'exposition à un agent neurotoxique